NASDAQ:RETA - Reata Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $89.22 -2.13 (-2.33 %) (As of 05/23/2019 10:49 AM ET)Previous Close$91.35Today's Range$88.86 - $90.9952-Week Range$30.76 - $104.53Volume822 shsAverage Volume188,324 shsMarket Capitalization$2.68 billionP/E RatioN/ADividend YieldN/ABeta2.91 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas. Receive RETA News and Ratings via Email Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RETA Previous Symbol CUSIPN/A CIK1358762 Webhttp://www.reatapharma.com/ Phone972-865-2219Debt Debt-to-Equity Ratio5.23 Current Ratio5.19 Quick Ratio5.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$53.59 million Price / Sales50.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-594.80Profitability EPS (Most Recent Fiscal Year)($2.87) Net Income$-80,550,000.00 Net Margins-392.80% Return on EquityN/A Return on Assets-36.58%Miscellaneous Employees123 Outstanding Shares30,060,000Market Cap$2.68 billion Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions What is Reata Pharmaceuticals' stock symbol? Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA." How were Reata Pharmaceuticals' earnings last quarter? Reata Pharmaceuticals Inc (NASDAQ:RETA) released its earnings results on Thursday, May, 9th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.97) by $0.01. The business earned $7.77 million during the quarter, compared to analysts' expectations of $7.92 million. View Reata Pharmaceuticals' Earnings History. When is Reata Pharmaceuticals' next earnings date? Reata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Reata Pharmaceuticals. What price target have analysts set for RETA? 5 Wall Street analysts have issued twelve-month price targets for Reata Pharmaceuticals' shares. Their predictions range from $92.00 to $139.00. On average, they anticipate Reata Pharmaceuticals' stock price to reach $111.80 in the next year. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals. What is the consensus analysts' recommendation for Reata Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals. What are Wall Street analysts saying about Reata Pharmaceuticals stock? Here are some recent quotes from research analysts about Reata Pharmaceuticals stock: 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (5/15/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 PT on RETA. Reata reported 4Q18 financial performance including collaboration revs of $7.9M, total expenses of $130.5M and cash of $338M. We project current cash to be sufficient to fund operations through 2020, including the three ongoing pivotal trials of bardoxalone in Alport syndrome and CTD-PAH, and omaveloxolone in Friedreich’s ataxia. We see 2019 as a potentially transformational year for the company, with two pivotal trial readouts in the second half and increasing visibility on a broadening set of bard’ indications going forward to further drive shares." (2/28/2019) Has Reata Pharmaceuticals been receiving favorable news coverage? Media headlines about RETA stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Reata Pharmaceuticals earned a news impact score of -3.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. Who are some of Reata Pharmaceuticals' key competitors? Some companies that are related to Reata Pharmaceuticals include Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and GALAPAGOS NV/S (GLPG). What other stocks do shareholders of Reata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Archrock (AROC), Targa Resources (TRGP), Precision Drilling (PD) and Celgene (CELG). Who are Reata Pharmaceuticals' key executives? Reata Pharmaceuticals' management team includes the folowing people: Mr. J. Warren Huff, Chairman, CEO & Pres (Age 65)Dr. Colin J. Meyer, Chief Medical Officer & Exec. VP of Product Devel. (Age 40)Dr. Keith W. Ward, Consultant (Age 49)Mr. Jason D. Wilson, CFO & Exec. VP of Strategy (Age 49)Ms. Elaine Castellanos, VP of Fin. & Accounting When did Reata Pharmaceuticals IPO? (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO. Who are Reata Pharmaceuticals' major shareholders? Reata Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Emerald Advisers LLC (1.32%), Emerald Mutual Fund Advisers Trust (1.21%), Candriam Luxembourg S.C.A. (0.84%), Northern Trust Corp (0.78%) and Geode Capital Management LLC (0.73%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, Jason Douglas Wilson, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals. Which institutional investors are selling Reata Pharmaceuticals stock? RETA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Emerald Advisers LLC, Prosight Management LP, JPMorgan Chase & Co., Man Group plc and First Trust Advisors LP. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Edward Bass, Jason Douglas Wilson and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals. Which institutional investors are buying Reata Pharmaceuticals stock? RETA stock was bought by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Rice Hall James & Associates LLC, Federated Investors Inc. PA, Candriam Luxembourg S.C.A., Goldman Sachs Group Inc., GAM Holding AG, Geode Capital Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals. How do I buy shares of Reata Pharmaceuticals? Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Reata Pharmaceuticals' stock price today? One share of RETA stock can currently be purchased for approximately $90.47. How big of a company is Reata Pharmaceuticals? Reata Pharmaceuticals has a market capitalization of $2.72 billion and generates $53.59 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe. What is Reata Pharmaceuticals' official website? The official website for Reata Pharmaceuticals is http://www.reatapharma.com/. How can I contact Reata Pharmaceuticals? Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected] MarketBeat Community Rating for Reata Pharmaceuticals (NASDAQ RETA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 209 (Vote Underperform)Total Votes: 440MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Understanding debt-to-equity ratio in fundamental analysis Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.